TRANSVAC

UNIL | Université de Lausanne
Vaccine Formulation Laboratory

The first TRANSVAC training course on "Practical approaches to vaccine development" 3-6 September 2012

Held at the Vaccine Formulation Laboratory, University of Lausanne, Switzerland

A second course will be organized in 2013 at the VFL. Further information will be posted on the TRANSVAC webpage later this year: www.transvac.org/Training-courses

Overview

The first TRANSVAC training course on "Practical approaches to vaccine development" was held on 3-6 September 2012 at the Vaccine Formulation Laboratory (VFL) training center, University of Lausanne, Switzerland. The course, which is funded by the European Commission's Seventh Framework Program, aimed to provide an overview of all parts of the vaccine development pipeline. Fifteen participants working in vaccine development were selected through a competitive process to attend the training course. Participants' course registration fees and hotel accommodation costs were covered by the TRANSVAC project. Twenty-six experts from industry, academia, government institutions, public bodies, and consultants presented numerous aspects of vaccine development providing a thorough overview of the vaccine development process.

Course Agenda

The TRANSVAC training agenda covered a four-day full-time training course. On the first morning, an overview of the general vaccine development field was given by:

Odile Leroy (European Vaccine Initiative)
"Introduction to the European vaccine landscape"

Suresh Jadhav (Serum Institute of India)
"Vaccine development in the 21st century"

Lorenzo Tolleri (Novartis Vaccines and Diagnostics)
"Business development and licensing aspects"

Martin Friede (World Health Organization)
"Introduction to the process development strategy"

This was followed by presentations on various vaccine antigen systems. The second day was dedicated to vaccine chemistry, manufacturing and quality control, including fermentation and media, downstream processing and formulation. The preclinical development of vaccines was covered on the third day. Finally, several facets of the clinical evaluation of vaccines were presented on the fourth day, which ended with a lively panel discussion. In addition, time for discussion was allocated after each talk and during breaks, in order to allow participants to interact with the presenters:

Arno van der Ark (RIVM), Barry Walker (Aeras), Blaise Genton (CHUV), Dexiang Chen (PATH), Ed Remarque (BPRC), Eddy Rommel (Rommel Consulting Partners), Gerrit-Jan Wennink (Wennink Consultancy & Interim Management), Giampietro Corradin (UNIL), Giuseppe Pantaleo (CHUV), Gwyn Davies (SGUL), Indresh Srivastava (Protein Sciences Corporation), Jan Langermans (BPRC), Lars Hangartner (UZH), Luc Hessel (LSL-Consult), Martin Comberbach (Comberbach Consulting Ltd.), Matt Cottingham (University of Oxford), Patrice Dubois (UNIL), Pieter Neels (FAMHP), Ralf Fehrenbach (Fehrenbach Consult SPRL), Roland Dobbelaer (Senior Consultant), Sodiomon Sirima (CNRFP), Sudeep Kothari (IVI)

Feedback from the participants

"The course offered an immense amount of valuable knowledge to me"
"I got to realize how complex it is to develop a vaccine that can successfully reach the market"
"The training has provided me with a network of people that I may consult for advice in the future"
"Delighted to hear such speakers and would like to thank TRANSVAC for the opportunity to attend"
"Extraordinary experience in terms of understanding on how this field works"

Further information can be found at: http://www.transvac.org/Training-courses